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DESTABILIZATION OF THE MEDIAL MENISCUS AS A MODEL FOR THE
STUDY OF PAIN PATHWAYS ASSOCIATEDWITH DEVELOPMENT OF
MURINE OSTEOARTHRITIS
R. Das1, A. Plaas1, J.D. Sandy1, M.D. Tortorella2, A.-M. Malfait1
1Rush Univ. Med. Ctr., Chicago, IL; 2Guangzhou Inst. of BioMed. Hlth.,
Guangzhou, China
Purpose: Pain is the major symptom in osteoarthritis (OA) and one of
the leading causes of impaired mobility in the elderly. There is no simple
correlation between pathological changes in the joint and pain severity. No
animal models adequately describe the correlation between joint structure
and symptoms, and very few have properly examined mechanisms of OA
pain generation. We recently reported that, following DMM in the right
knee, C57BL/6 mice develop rapid-onset progressive mechanical allodynia
in the ipsilateral hindpaw only, as early as 2 weeks and developing over
8 weeks post DMM surgery. Adamts5 knockout (KO) mice, which do not
develop OA-like structural changes after DMM, did not develop allodynia.
Our long-term goal is to quantitatively measure pain and dissect molecular
pathways involved in pain generation in a mouse model of OA. We chose
destabilization of the medial meniscus (DMM) in C57BL/6 mice because,
unlike other rodent OA models, the joint pathology in this model is slowly
progressive over 16 weeks and thus optimally suited for studying pain at
different stages of disease.
Methods: DMM surgery was performed in the right knee of 10-week old
male C57BL/6 mice. At different time points after surgery (2, 4, 8, 12 and
16 weeks), pain was assessed in DMM operated mice, in sham controls and
in age-matched naïve controls. Pain-dependent measures included 1) von
Frey analysis to measure mechanical allodynia; and 2) behavioral moni-
toring with Laboras™ equipment, which quantiﬁes activity using pattern
recognition software, including total distance traveled over a speciﬁed time
period. Concurrently, innervating dorsal root ganglia (DRG) L2-L5 were
harvested from both the operated and the non-operated side at different
time points after surgery for RT-PCR analysis. Knee joints were collected
for histopathology or India ink staining.
Results: In the current studies, we found that the unilateral mechanical
allodynia subsided 8-16 weeks after DMM surgery. Total distance traveled
over a speciﬁed period was relatively constant over the ﬁrst 8 weeks after
surgery, but decreased from 12 weeks after surgery. RT-PCR analysis of
innervating DRG at different time points (4, 8, 16 weeks) following DMM
revealed signiﬁcantly increased levels of mRNA (compared to naïve age-
matched controls) for the neurotrophic factors, NGF (nerve growth factor)
and GDNF (glial cell-derived neurotrophic factor), and for the chemokine,
MCP-1 at the 8-week time point. mRNA levels were elevated in both the
ipsi- and in the contralateral DRG (but more so in the ipsilateral DRG).
mRNA levels for substance P or for the NGF receptor, TrkA, were not
elevated (Figure 1). mRNA levels for the genes studied were not elevated in
Adamts5 KO mice.
Figure 1
Conclusions: Time-course experiments in the murine DMM model of OA
enable us to quantify pain at different stages of disease. Pain-related
outcome measures in the DMM model can essentially be divided into an
early stage (wk 2-8, allodynia only) and a late stage (wk 8-16, resolution
of allodynia and appearance of reduced locomotion). Increased mRNA
levels for neurotrophic factors and for MCP-1 in the innervating DRG
were detectable 8 weeks after surgery. These observations suggest that
the DMM model is suitable for studying mechanisms of chronic OA pain
generation.
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RUNT-RELATED TRANSCRIPTION FACTOR 2 ALLELES AND KNEE
CARTILAGE LESIONS ARE ASSOCIATEDWITH INCREASES IN KNEE PAIN
OVER 5 YEARS IN OLD ADULTS
C. Ding1, A. Stephens2, F. Cicuttini3, N. Morrison2, G. Jones1
1Univ. of Tasmania, Hobart, Australia; 2Griﬃth Univ. Gold Coast Campus, Gold
Coast, Australia; 3Monash Univ., Melbourne, Australia
Purpose: Runt-related transcription factor 2 (RUNX-2) is the pivotal
transcription factor for chondrocyte hypertrophy. This study aimed to de-
termine if RUNX-2 and knee cartilage lesions were associated with change
in knee pain over 5 years in older adults.
Methods: A total of 755 randomly selected subjects (mean 62 years, range
51-81, 50% female) were studied at baseline, 2.9 and 5 years later. Knee
pain (on ﬂat surface, going up/down stairs, at night, sitting/lying and
standing upright) at baseline and 5 years was assessed using WOMAC.
RUNX-2 alleles (BB, Bb and bb) were genotyped at baseline. Fat-suppressed
MRI of the right knee was performed to determine knee cartilage volume
and defects at baseline and 2.9 years.
Results: In multivariable analysis, RUNX-2 b allele (Bb 11.8% and bb 1.4%)
was associated with a borderline increase in total knee pain score (≥1) (OR
1.89, P=0.06), an increase in knee pain at night (OR 2.61, P=0.012) and an
increase in sitting/lying knee pain (2.51, P=0.028) over 5 years. Increase in
total knee pain score over 5 years was associated with female sex (OR 2.2,
P=0.03), body mass index (OR 1.07 per kg/m2, P=0.004), knee radiographic
osteoarthritis (OR 2.03 per grade, P=0.006), medial tibiofemoral cartilage
defects (OR 1.46 per grade, P=0.006), lateral tibiofemoral cartilage defects
(OR 1.38 per grade, P=0.025), change in medial cartilage defects over 2.9
years (OR 1.68 per grade, P=0.004) and loss of medial tibial cartilage volume
over 2.9 years (OR 1.07 per percent loss, P=0.03).
Conclusions: Multiple factors contribute to an increase in knee pain over 5
years. This is the ﬁrst study to report that the RUNX-2 b allele predicts in-
creased knee pain. Cartilage lesions are related to knee pain, independently
of potential confounders.
037
THE CATHEPSIN K INHIBITOR AZ12606133 REDUCES ARTICULAR
CARTILAGE BREAKDOWN AND JOINT PAIN IN OSTEOARTHRITIC KNEES
J.J. McDougall1, N. Schuelert1, J. Bowyer2
1Univ. of Calgary, Calgary, AB, Canada; 2AstraZeneca, Loughborough, United
Kingdom
Purpose: The aim of the present study was to evaluate the chondropro-
tective and pain modulating effects of a novel cathepsin K inhibitor
AZ12606133 in the Dunkin-Hartley guinea pig model of spontaneous
osteoarthritis (OA).
Methods: Nineteen mature (9 month old) Dunkin Hartley guinea pigs were
chronically implanted with an Alzet osmotic pump (2.5μl/hr; total volume =
2ml) which was set to deliver either the cathepsin K inhibitor AZ12606133
(0.5μg/kg/day, n=10) or vehicle (n=9). On day 28 of treatment, urine was
collected over a 6 hour period by placing guinea pigs in metabolism cages.
The urine was stored at -20[[Unsupported Character - &#61616;]]C until
later analysed for evidence of cartilage degradation using the cross-linked
C-telopeptides of type II (CTXII) collagen assay. Animals were then prepared
for electrophysiological recording of knee joint primary afferent nerves.
Recordings from mechanosensory nerves were made at rest (spontaneous
activity) and in response to rotation of the knee either in the normal
working range (40mNm) or the noxious range (60mNm).
Results: AZ12606133 caused a 63% reduction in urinary CTXII levels com-
pared to vehicle treated guinea pigs (Figure A). Spontaneous afferent ﬁring
rate in vehicle-treated animals was 52.9±14 action potentials/min (n = 26
